HALIFAX, Nova Scotia, Dec. 21, 2021 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRA™ product line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test (VYRA™ CoV2Flu). Based on MedMira’s proprietary technology, this 3-in-1 test is developed to distinguish between SARS-CoV-2 and Influenza A or B infections. Furthermore, the Company takes advantage of the latest regulatory development surrounding the US FDA De Novo/510(k) clearance processes by applying for its COVID-19 products. Read More